All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells

Li, Ruo‐Jing; Xue, Yingwei; Zhang, Yan; Ju, Rui-Jun; Wang, Xiaoxing; Yao, Hong-Juan; Men, Ying; Tian, Wei; Yu, Yang; Zhang, Liang; Huang, Ren-Jie; Lü, Wan-Liang

doi:10.1016/j.jconrel.2010.10.019

Cited by 110 publications

(66 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In practice, delivering drugs into the rare population of CSCs in tumor tissue is still challenging. Recently, studies of nanoparticle delivery systembased approaches to tackle the CSC problem have been reported [18,19]. The superior performance of nanoparticles show some therapeutic advantages for CSCs therapy as well, such as enrichment of therapeutic agents within CSCs and delivery of more than one functional agent to CSCs [20,21].…”

Section: Introductionmentioning

confidence: 99%

“…The superior performance of nanoparticles show some therapeutic advantages for CSCs therapy as well, such as enrichment of therapeutic agents within CSCs and delivery of more than one functional agent to CSCs [20,21]. Several studies have successfully targeted and eliminated CSCs using a nanoparticle mediated delivery system, showing good results in overcoming tumor drug resistance and relapse [19,22]. Our previous studies also demonstrated that dual pH-sensitive polymeredrug conjugate nanoparticles showed enhanced inhibition to the progression of drug-resistant SK-3rd cancer stem cells [23], and gold nanoparticles conjugated with doxorubicin via hydrazone bonds can deliver more doxorubicin (DOX) to CSCs by overcoming drug resistance through evading the efflux of P-gp, resulting in the removal of all tumor cell sub-populations and averting the potential repopulation of the tumor mass by CSCs [24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells

et al. 2015

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells

et al. 2015

View full text Add to dashboard Cite

“…In this report for the first time we are showing simultaneous distribution of PEGylated coumarin-6 liposomes between healthy and cancerous tissue. Though there are several reports describing the use of coumarin-6 liposomes to investigate the cellular uptake but these studies have been limited to in vitro imaging only [36][37][38].…”

Section: Oral Telmisartan Controlmentioning

confidence: 99%

Tumor Stromal Disrupting Agent Enhances the Anticancer Efficacy of Docetaxel Loaded PEGylated Liposomes in Lung Cancer

Patel

Doddapaneni

Chowdhury

et al. 2016

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Aim: Therapeutic efficacy of anticancer nanomedicine is compromised by tumor stromal barriers. The present study deals with the development of docetaxel loaded PEGylated liposomes (DTXPL) and to investigate the effect of tumor stroma disrupting agent, telmisartan, on anticancer efficacy of DTXPL. Methods: DTXPL was prepared using proprietary modified hydration method. Effect of oral telmisartan treatment on tumor uptake of coumarin-6 liposomes and anticancer efficacy of DTXPL was evaluated in orthotopic xenograft lung tumor bearing mice. Results: DTXPL (105.7 ± 3.8 nm) showed very high physical stability, negligible hemolysis, 428% enhancement in bioavailability with significantly higher intratumoral uptake. Marked reduction in collagen-I, MMP2/9 and lung tumor weight were observed in DTXPL+telmisartan group. Conclusion: Combination of DTXPL with telmisartan could significantly enhance clinical outcome in lung cancer. Lung cancer is by far the most common cause of cancer related mortality in both men and women. Non-small-cell lung cancer (NSCLC) accounts for 87% of total cases of lung cancer with overall 5-year survival rate less than 18.2% [1,2]. Depending on the stage of lung cancer and condition of patients, the chemotherapeutic regimen for lung cancer includes following drugs: Cisplatin/carboplatin or paclitaxel/docetaxel, etoposide, vinorelbine, erlotinib or other tyrosine kinase inhibitors, gemcitabine and pemetrexed. Despite recent advances in diagnosis and treatment, the clinical outcome amongst NSCLC patients is still not impressive. Docetaxel (DTX) is one the most widely used for drug for the treatment of various types of solid tumor including ovarian, breast, lung and head/neck cancers. Docetaxel has extremely poor water solubility and rapid precipitation tendency, which necessitates very high concentration of ethanol and surfactant for its intravenous injection. Tween 80 in Taxotere ® formulation is responsible for severe life threatening hypersensitivity and peripheral neuropathy [3,4]. A safer formulation to enhance patient compliance and therapeutic efficacy of DTX is always in demand. As a result, current research is mainly focused on developing nanomedicinal formulation such as liposomes, polymeric micelles, albumin nanoparticles, polymer drug conjugates, etc. Liposomes are the most versatile nanocarrier with superior biocompatibility and large scale manufacturing feasibility compared to other types of nanocarrier. Abraxane ® ,

show abstract

“…Increasing evidence has demonstrated that functionalized liposomes are able to maintain the nature of pegylated liposomes -which show enhanced permeability and retention (EPR) effects in tumor tissues -and to potentiate the killing effect in drug-resistant cancer and in cancer stem cells through varying mechanisms and signaling pathways. [20][21][22] In the present study, we prepared functional epirubicin liposomes modified with 1,2-distearoyl-sn-glycero-3 -phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG 2000 ) and dequalinium. The present study aimed to characterize the capability of these functional epirubicin liposomes to modulate mitochondria to eliminate refractory cancers.…”

Section: Introductionmentioning

confidence: 99%

The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer

Liu

Yan

et al. 2017

IJN

Self Cite

View full text Add to dashboard Cite

Currently, chemotherapy is less efficient in controlling the continued development of breast cancer because it cannot eliminate extrinsic and intrinsic refractory cancers. In this study, mitochondria were modified by functional epirubicin liposomes to eliminate refractory cancers through initiation of an apoptosis cascade. The efficacy and mechanism of epirubicin liposomes were investigated on human breast cancer cells in vitro and in vivo using flow cytometry, confocal microscopy, high-content screening system, in vivo imaging system, and tumor inhibition in mice. Mechanistic studies revealed that the liposomes could target the mitochondria, activate the apoptotic enzymes caspase 8, 9, and 3, upregulate the proapoptotic protein Bax while downregulating the antiapoptotic protein Mcl-1, and induce the generation of reactive oxygen species (ROS) through an apoptosis cascade. In xenografted mice bearing breast cancer, the epirubicin liposomes demonstrated prolonged blood circulation, significantly increased accumulation in tumor tissue, and robust anticancer efficacy. This study demonstrated that functional epirubicin liposomes could significantly induce programmed death of refractory breast cancer by activating caspases and ROS-related apoptotic signaling pathways, in addition to the direct killing effect of the anticancer drug itself. Thus, we present a simple nanomedicine strategy to treat refractory breast cancer.

show abstract

All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells

Cited by 110 publications

References 44 publications

Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells

Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells

Tumor Stromal Disrupting Agent Enhances the Anticancer Efficacy of Docetaxel Loaded PEGylated Liposomes in Lung Cancer

The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer

Contact Info

Product

Resources

About